Retour
Prix Kuros Biosciences AG (CSBTF)
Graphique du cours de l'action CSBTF
CSBTF Gagner
Kuros Biosciences AG
$34.65
0%
$0
À la fermeture : Jan 23, 16:00:00 GMT-5
$34.65
0%
$0
Post-Marché: Jan 23, 20:00:00 GMT-5
Earnings FAQ
Comment le bénéfice par action récent de CSBTF se compare-t-il aux attentes ?
Comment les revenus de Kuros Biosciences AG CSBTF se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Kuros Biosciences AG ?
Quel est le score de qualité des bénéfices pour Kuros Biosciences AG ?
Quand Kuros Biosciences AG publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Kuros Biosciences AG ?
Kuros Biosciences AG a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$34.65
Prix d'ouverture
$34.65
Plage de la journée
$34.65 - $34.65
Plage de 52 semaines
$19.43 - $42.81
Volume
600
Volume moyen
58
BPA (TTM)
-0.19
Rendement en dividend
--
Capitalisation boursière
$1.3B
Qu’est-ce que Kuros Bioscience Ltd. ?
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. The company is headquartered in Schlieren, Zuerich and currently employs 122 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved